NO20051941L - Kombinasjonskjemoterapisammensetninger og fremgangsmater. - Google Patents

Kombinasjonskjemoterapisammensetninger og fremgangsmater.

Info

Publication number
NO20051941L
NO20051941L NO20051941A NO20051941A NO20051941L NO 20051941 L NO20051941 L NO 20051941L NO 20051941 A NO20051941 A NO 20051941A NO 20051941 A NO20051941 A NO 20051941A NO 20051941 L NO20051941 L NO 20051941L
Authority
NO
Norway
Prior art keywords
methods
combination chemotherapy
compositions
chemotherapy compositions
combination therapies
Prior art date
Application number
NO20051941A
Other languages
English (en)
Inventor
Graham Edmund Kelly
Original Assignee
Novogen Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen Res Pty Ltd filed Critical Novogen Res Pty Ltd
Publication of NO20051941L publication Critical patent/NO20051941L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Denne oppfinnelsen angår kombinasjonsterapier som involverer antikreft kjemoterapeutiske midler og isoflavoner eller analoger derav. Oppfinnelsen angår videre forbindelser, sammensetninger, fremgangsmåter og terapeutiske anvendelser som involverer, inneholder, omfatter, inkluderer og/eller for fremstilling platinaisoflavonoidkomplekser egnet for anvendelse i kombinasjonsterapiene ifølge oppfinnelsen.
NO20051941A 2002-10-02 2005-04-20 Kombinasjonskjemoterapisammensetninger og fremgangsmater. NO20051941L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002951833A AU2002951833A0 (en) 2002-10-02 2002-10-02 Compositions and therapeutic methods invloving platinum complexes
PCT/AU2003/001296 WO2004030662A1 (en) 2002-10-02 2003-10-02 Combination chemotherapy compositions and methods

Publications (1)

Publication Number Publication Date
NO20051941L true NO20051941L (no) 2005-04-20

Family

ID=28679466

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051941A NO20051941L (no) 2002-10-02 2005-04-20 Kombinasjonskjemoterapisammensetninger og fremgangsmater.

Country Status (10)

Country Link
US (2) US7906554B2 (no)
EP (1) EP1545481A4 (no)
JP (1) JP2006504705A (no)
CN (1) CN100591331C (no)
AU (1) AU2002951833A0 (no)
CA (1) CA2498555A1 (no)
MX (1) MXPA05003528A (no)
NO (1) NO20051941L (no)
NZ (1) NZ538583A (no)
WO (1) WO2004030662A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US20080131968A1 (en) * 2002-08-28 2008-06-05 Nomir Medical Technologies, Inc. Near-infrared electromagnetic modification of cellular steady-state membrane potentials
CA2542351A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd. Combinational radiotherapy and chemotherapy compositions and methods
CA2581316C (en) 2004-09-21 2013-09-10 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
AU2007314141A1 (en) * 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
US8292723B2 (en) * 2007-11-09 2012-10-23 Igt Gaming system and method for providing team play
CA2715348A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
CA2738510A1 (en) * 2008-07-30 2010-02-04 Novogen Research Pty Ltd 6-substituted isoflavonoid compounds and uses thereof
WO2011026219A1 (en) * 2009-09-01 2011-03-10 Lu qing-bin Combination therapy for cancer comprising a platinum -based antineoplastic agent and a biocompatible electron donor
EP2635273B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
CN103494838B (zh) * 2013-09-30 2016-05-11 武汉大学 一种化疗药物组合物
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗
CA3058503A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
EP3439651A4 (en) * 2016-04-06 2019-10-30 Noxopharm Limited IMPROVEMENTS IN CANCER TREATMENT
CA3058492A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
EP3445347B1 (en) * 2016-04-22 2022-03-30 Noxopharm Limited Chemotherapy improvements with idronoxil
JP7123945B2 (ja) 2016-10-03 2022-08-23 シャー，ホウン・サイモン がん放射線療法を増強するための組成物および方法
US10905724B2 (en) 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing hyperthermia therapy
JP7788129B2 (ja) 2017-06-13 2025-12-18 シャー，ホウン・サイモン 癌化学療法を増強するための組成物および方法
JP7336993B2 (ja) 2017-06-13 2023-09-01 シャー，ホウン・サイモン 癌放射線療法を増強する組成物および方法
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264509A (en) * 1977-06-08 1981-04-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
JP2514500B2 (ja) * 1991-09-14 1996-07-10 呉羽化学工業株式会社 多剤耐性抑制剤及び発現阻害剤
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
AU3456499A (en) * 1998-03-30 1999-10-18 University Of Mississippi, The Isoflavones for treating giardiasis and malaria
FR2781154B1 (fr) * 1998-07-15 2001-09-07 Lafon Labor Composition therapeutique a base d'isoflavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
AUPP868599A0 (en) 1999-02-15 1999-03-11 Novogen Research Pty Ltd Production of isoflavone derivatives
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
FI20001593A7 (fi) 2000-07-03 2002-01-04 Orion Yhtymo Oyj Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
CN1335133A (zh) * 2000-07-28 2002-02-13 蛋白质技术国际公司 预防或治疗乳腺癌的组合物和方法
WO2003086386A1 (en) 2002-04-09 2003-10-23 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures

Also Published As

Publication number Publication date
MXPA05003528A (es) 2005-06-03
EP1545481A4 (en) 2009-11-11
US7906554B2 (en) 2011-03-15
JP2006504705A (ja) 2006-02-09
US20060183728A1 (en) 2006-08-17
WO2004030662A1 (en) 2004-04-15
NZ538583A (en) 2008-03-28
CA2498555A1 (en) 2004-04-15
HK1083455A1 (zh) 2006-07-07
CN100591331C (zh) 2010-02-24
EP1545481A1 (en) 2005-06-29
US20080069900A1 (en) 2008-03-20
CN1694690A (zh) 2005-11-09
AU2002951833A0 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
NO20051941L (no) Kombinasjonskjemoterapisammensetninger og fremgangsmater.
SE0301700D0 (sv) Novel compounds
CY1116373T1 (el) Φαρμακευτικα σκευασματα που περιεχουν μεθυλναλτρεξονη
NO20063171L (no) Endoparasitisidale sammensetninger for topisk anvendelse
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
SE0301653D0 (sv) Novel compounds
NO20064584L (no) Tetrahydropyridoindolderivater
NO20005535D0 (no) Pyrazol-derivater som P-38 MAP kinase-inhibitorer
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20066055L (no) Pyridinderivater
CY1113282T1 (el) Αντιικα νουκλεοζιτικα αναλογα
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
DE60212949D1 (de) Antivirale pyrazolopyridin verbindungen
DE60334536D1 (de) Furylverbindungen
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
SG149077A1 (en) Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists
SE0303541D0 (sv) New compounds
UA83648C2 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
NO20062739L (no) Kontrollert frigivining av topirimat i flytende doseringsform
SE0401871D0 (sv) New compositions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application